74- year-old man with LRMDS and Transfusion Dependent Anemia
EP: 1.ESA-Ineligible LR MDS patient with Transfusion-Dependent Anemia
EP: 2.Therapy Selection for ESA Ineligible LR-MDS Patients
EP: 3.Mechanism of Action: Imetelstat in LR MDS
EP: 4.Efficacy and Safety of Imetelstat in ESA- ineligible patients
EP: 5.Adverse Event Profile & Management of Imetelstat
EP: 6.Comparing Telomerase Inhibitors and EMAs in ESA-Ineligible LR MDS
EP: 7.74- year-old man with LRMDS and Transfusion Dependent Anemia
EP: 8.Efficacy and Safety of 2L therapies for RS+ patients
EP: 9.EMA vs Telomerase Inhibitor for RS+ patients after ESA failure
EP: 10.Optimizing Anemia Management and Addressing Unmet Needs in LR MDS
Clinical Presentation: 74-year-old man diagnosed 1 years ago with LR-MDS with moderate anemia (Hb 11.2 g/dL) Non-del(5q)
• No family history of cancer or significant genotoxic agent exposure
• Serum EPO - 250m U/L, Ring sideroblast (RS) positive • IPSS-R: Low
• Received 2 units of blood every 2 months for 4 months; at that point they started therapy with ESAs.
• At 12 weeks, Hb remained essentially the same (11.4 g/dL) and transfusion needs decreased.
• At 20 weeks, his Hb is now 10.8 g/dL and he now is requiring 2-3 units of blood every month.
AFFINITY Study Completes Enrollment for Novel Aliya PEF System in Advanced Lung Cancer
August 9th 2024The AFFINITY study has finished enrolling participants to evaluate the Aliya pulsed electric field system in patients with stage IV non–small cell lung cancer or lung metastases who are not candidates for surgery.
Read More
